• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
    • РусскийРусский
  • Menu

10 popular drugs that are about to lose their patents

14.04.2017/in News /by X7 Research

The expiration of patent law is one of the key factors for pharmaceutical companies, so it is not surprising that the pharmaceutical companies are trying to extend it: expanding indications for use, studying actions for different age groups of patients, etc.

The US pharmaceutical market is a tasty morsel for drug manufacturers around the world, so the loss of patent protection may be of interest to many pharmaceutical companies, and for manufacturers of original drugs to mean a serious decline in income.

We present you a selection of 10 drugs, which are likely to lose patent protection in the US in 2017.

  1. A drug for the treatment of multiple sclerosis Copaxone (glatiramer acetate) by Teva Pharmaceutical Industries.

Revenue from sales in the US in 2016 amounted to 3.479 billion dollars.

  1. The drug for the treatment of erectile dysfunction Cialis (tadalafil) company “Eli Lilly”.

Revenue from drug sales in the US in 2016: $ 1.469 billion. According to Evaluate, Cialis’s sales in monetary terms are about 14% of Eli Lilly’s sales revenue globally and 16% in the US.

  1. Viagra (sildenafil) company Pfizer.

In 2016, sales of a well-known drug for the treatment of erectile dysfunction in the US amounted to 1.148 billion dollars, and the term of its patent protection is coming to an end already in December this year.

  1. The drug for the treatment of multiple myeloma Velcade (bortezomib) of the company Takeda.

Revenue from sales in the US in 2016 amounted to 1.13 billion dollars. Patent protection ends in 2017, and by 2022, analysts estimate that the sales of Velcade (bortezomib) in the US will drop to $ 187 million.

  1. Antiviral drug for the treatment of HIV infections Sustiva (efavirenz) of the company “Bristol-Myers Squibb”.

Revenue from drug sales in the US in 2016 amounted to 901 million dollars, and the expiry date of the patent is coming to an end already in December 2017.

  1. Sandostatin LAR (octreotide) from Novartis.

Sales of the drug for the treatment of acromegaly, a disorder caused by excess production of growth hormone that affects less than 20,000 patients in the US, brought Novartis $ 853 million in 2016. Patent protection for the drug came to an end in January of the current year.

  1. Norditropin SimpleXx (somatotropin) from Novo Nordisk.

The drug for the treatment of disruption of the growth process among children with insufficient endogenous growth hormone, chronic renal failure among children accompanied by growth retardation, Shereshevsky-Turner syndrome, osteoporosis, and immunodeficiency syndrome, accompanied by a decrease in body weight, loses its patent protection in December 2017. And the proceeds from the sale of the drug in the US in 2016 amounted to 642.5 million dollars.

  1. Viread (tenofovir disoproxil fumarate) from Gilead Sciences.

Viread is a class of antiretroviral drugs known as reverse transcriptase inhibitors of nucleotide analogs that block reverse transcriptase, the most important viral enzyme in the human immunodeficiency virus-1 (HIV-1).

Revenue from drug sales in the US in 2016 amounted to 591 million dollars.

  1. Antidepressant Pristiq (desvenlafaxine) of the company “Pfizer”.

The term of patent protection of the drug ended in March this year, bringing “Pfizer” 578 million dollars from sales in the United States.

  1. Strattera (atomoxetine) of the company “Eli Lilly”.

The drug Strattera (atomoxetine), intended for the treatment of attention deficit hyperactivity disorder, brought Eli Lilly $ 535 million in 2016, and the patent loss will occur in May of this year.

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Readability User Testing of Package Information Leaflets (PIL) in EAEU
Read More
Publications
Remote clinical trial monitoring
Read More
Publications
Post-authorization studies of drug safety in Russia
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

1 + 1 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
X7 Research will take part in the DIA 2017 international conference European regulatory stuff supports simple approach to biosimilars
Scroll to top